Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

has now also been approved by the U.S. Food and Drug Administration to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday. A Phase 3 clinical trial found ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Semaglutide, a medication already widely ... highlight a 24% reduction in major kidney disease events among patients with chronic kidney disease (CKD). This breakthrough opens up new possibilities ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

SCIENTISTS BELIEVE SEMAGLUTIDE CAN PREVENT HEART ATTACK ... Administration to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday.Video above: Studies ...